Momelotinib

Drug Profile

Momelotinib

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Cytopia Research
  • Developer Gilead Sciences
  • Class Antineoplastics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 16 Nov 2016 Top-line efficacy and adverse events data from the SIMPLIFY-1 phase III trial in Myelofibrosis, essential thrombocythaemia and polycythaemia vera released by Gilead
  • 16 Nov 2016 Top-line efficacy data from the SIMPLIFY-2 phase III trial in Myelofibrosis, essential thrombocythaemia and polycythaemia vera released by Gilead
  • 30 Jun 2016 Gilead completes a phase III trial in Myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in USA, United Kingdom, Taiwan, Sweden, Spain, Singapore, Romania, Poland, Netherlands, South Korea, Japan, Hungary, Germany, France, Denmark, Czech Republic, Canada, Bulgaria, Belgium, Austria and Australia (NCT01969838)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top